We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.
- Authors
Censi, Simona; Di Stefano, Marta; Repaci, Andrea; Benvenuti, Teresa; Manso, Jacopo; Pagotto, Uberto; Iacobone, Maurizio; Barollo, Susi; Bertazza, Loris; Galuppini, Francesca; Benna, Clara; Pennelli, Gianmaria; Plebani, Mario; Faggian, Diego; Colombo, Carla; Fugazzola, Laura; Mian, Caterina
- Abstract
Background: Procalcitonin (proCt) was recently proposed as an alternative or in addition to calcitonin (Ct) in medullary thyroid cancer (MTC) diagnostics. Methods: Serum basal Ct (bCt) and proCt (bproCt) levels were measured before surgery from a consecutive series of patients with (n=43) and without (n=75) MTC, retrospectively collected in Padua. Serum bproCt, bCt and stimulated proCt and Ct (sproCt and sCt) were measured in another consecutive series of 33 patients seen at three tertiary-level institutions undergoing a calcium stimulation test prior to surgery, 20 of them with a final diagnosis of MTC, and 13 with non-MTC nodular disease. Results: Median bproCt levels were higher in MTC than in non-MTC. A positive correlation was found for bproCt with bCt (P<0.01, R2 = 0.75), and with tumor size (P<0.01, R2 = 0.39). The cut-off for bproCt differentiating between MTC and non-MTC patients was >0.07 ng/ml (sensitivity: 85.7%, specificity: 98.9%, positive predictive value [PPV]: 98.2%, negative predictive value [NPV]: 90.6%, P<0.01). While bproCt was >0.07 ng/ml in 38/39 (97.4%) patients with MTC >10 mm, it was above said cut-off only in 15/23 (65.2%) patients with tumors ≤10 mm. A sproCt >0.19 ng/ml was able to identify MTC [sensitivity: 90.0%, specificity:100.0%, PPV: 100.0%, NPV: 86.7% (P<0.01)]. Conclusions: Our data suggest that bproCt can be a good adjunct to Ct for MTC diagnostic purposes. In consideration of its high specificity, it can be used in combination with Ct in MTC diagnostics, particularly in the case of mildly elevated basal Ct levels.
- Subjects
PADUA (Italy); MEDULLARY thyroid carcinoma; CANCER diagnosis; CALCITONIN; THYROID cancer; DIAGNOSIS
- Publication
Frontiers in Endocrinology, 2021, Vol 12, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2021.754565